🔗 Permalink

Inventor profile of:

John W. Erickson

City:

Frederick, Maryland

Country:

United States

Published Applications:

13

Last publication date:

2011-07-07

Top Assignees for applications by John W. Erickson

The entities that hold a legal rights for patent applications filed by inventor Erickson John W.:

Sequoia Pharmaceuticals, Inc. 3 Gaithersburg, MD United States
The United States of America as Represented by the Department of Health and Human Services 3 Washington, DC United States
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2 Urbana, IL United States
Tibotec Pharmaceuticals Ltd. 1 Little Island, Ireland
CONJUCHEM BIOTECHNOLOGIES, INC. 1 Montreal, Canada
Government of the United States of America, represented by Secretary, Departmemt of Health and 1 Rockville, MD United States
TIBOTEC PHARMACEUTICALS LTD. 1 Co Cork, Ireland
The Board of Trustees of the University of Illinois 1 Urbana, IL United States
ConjuChem Biotechnologies Inc. 1 Montreal (Quebec), Canada
Government of the U.S.A., represented by the Secretary, Department of Health and Human Services 1 Rockville, MD United States
TIBOTEC PHARMACEUTICALS LTD. 1 County Cork, Ireland
The United States of America, as represented by the Secretary, Department of Health and Human Services 1 Washington, DC United States

Recent patent applications by Erickson John W.

John W. Erickson from Frederick, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2011-07-07

US20110166061A1

Chemistry; metallurgy

LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION

#2 | 2008-12-30

US9720276

Fitness assay and associated methods

#3 | 2008-04-10

US20080085918A1

Human necessities

Method of treating HIV infection

#4 | 2006-12-28

US20060293286A1

Chemistry; metallurgy

Resistant-repellent retroviral protease inhibitors

#5 | 2006-11-16

US20060258737A1

Chemistry; metallurgy

Resistance-repellent retroviral protease inhibitors

#6 | 2006-09-19

US10337349

Resistance-repellent retroviral protease inhibitors

#7 | 2006-09-14

US20060205002A1

Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins

#8 | 2006-08-08

US10161613

Methods for determining plasma free drug concentration by direct measurement of binding affinity of protease inhibitors to plasma proteins

#9 | 2005-11-24

US20050261364A1

Chemistry; metallurgy

Hexahydrofuro[2,3-B]furan-3-YL-N-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor

#10 | 2005-09-22

US20050208678A1

Anti-fusion assay

#11 | 2005-07-21

US20050158713A1

Human necessities

Fitness assay and associated methods

#12 | 2005-04-28

US20050090546A1

Chemistry; metallurgy

Aspartic protease inhibitors

#13 | 2005-03-24

US20050065075A1

Chemistry; metallurgy

Long lasting fusion peptide inhibitors for HIV infection

InventorID:

3547059 ⎘